Therapeutic use of calpeptin in COVID-19 infection.
This perspective considers the benefits of the potential future use of the cell permeant calpain inhibitor, calpeptin, as a drug to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Recent work has reported calpeptin's capacity to inhibit entry of the virus into cell...
| मुख्य लेखकों: | , , |
|---|---|
| स्वरूप: | लेख |
| भाषा: | English |
| प्रकाशित: |
Portland Press
2022
|
| विषय: | |
| ऑनलाइन पहुंच: | https://repository.londonmet.ac.uk/7994/2/cs-2022-0638.pdf |
| _version_ | 1825625750331457536 |
|---|---|
| author | Inal, Jameel Paizuldaeva, Ainura Terziu, Esmeralda |
| author_facet | Inal, Jameel Paizuldaeva, Ainura Terziu, Esmeralda |
| author_sort | Inal, Jameel |
| collection | LMU |
| description | This perspective considers the benefits of the potential future use of the cell permeant calpain inhibitor, calpeptin, as a drug to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Recent work has reported calpeptin's capacity to inhibit entry of the virus into cells. Elsewhere, several drugs, including calpeptin, were found to be able to inhibit extracellular vesicle (EV) biogenesis. Unsurprisingly, because of similarities between viral and EV release mechanisms, calpeptin has also been shown to inhibit viral egress. This approach, identifying calpeptin, through large-scale screening studies as a candidate drug to treat COVID-19, however, has not considered the longer term likely benefits of calpain inhibition, post-COVID-19. This perspective will reflect on the capacity of calpeptin for treating long COVID by inhibiting the overproduction of neutrophil extracellular traps potentially damaging lung cells and promoting clotting, together with limiting associated chronic inflammation, tissue damage and pulmonary fibrosis. It will also reflect on the tolerated and detrimental in vivo side-effects of calpain inhibition from various preclinical studies. |
| first_indexed | 2024-07-09T04:05:42Z |
| format | Article |
| id | oai:repository.londonmet.ac.uk:7994 |
| institution | London Metropolitan University |
| language | English |
| last_indexed | 2024-07-09T04:05:42Z |
| publishDate | 2022 |
| publisher | Portland Press |
| record_format | eprints |
| spelling | oai:repository.londonmet.ac.uk:79942022-11-11T11:49:24Z https://repository.londonmet.ac.uk/7994/ Therapeutic use of calpeptin in COVID-19 infection. Inal, Jameel Paizuldaeva, Ainura Terziu, Esmeralda 610 Medicine & health This perspective considers the benefits of the potential future use of the cell permeant calpain inhibitor, calpeptin, as a drug to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Recent work has reported calpeptin's capacity to inhibit entry of the virus into cells. Elsewhere, several drugs, including calpeptin, were found to be able to inhibit extracellular vesicle (EV) biogenesis. Unsurprisingly, because of similarities between viral and EV release mechanisms, calpeptin has also been shown to inhibit viral egress. This approach, identifying calpeptin, through large-scale screening studies as a candidate drug to treat COVID-19, however, has not considered the longer term likely benefits of calpain inhibition, post-COVID-19. This perspective will reflect on the capacity of calpeptin for treating long COVID by inhibiting the overproduction of neutrophil extracellular traps potentially damaging lung cells and promoting clotting, together with limiting associated chronic inflammation, tissue damage and pulmonary fibrosis. It will also reflect on the tolerated and detrimental in vivo side-effects of calpain inhibition from various preclinical studies. Portland Press 2022-10 Article PeerReviewed text en cc_by_nc_nd_4 https://repository.londonmet.ac.uk/7994/2/cs-2022-0638.pdf Inal, Jameel, Paizuldaeva, Ainura and Terziu, Esmeralda (2022) Therapeutic use of calpeptin in COVID-19 infection. Clinical science, 136 (20). pp. 1439-1447. ISSN 1470-8736 https://doi.org/10.1042/CS20220638 10.1042/CS20220638 10.1042/CS20220638 |
| spellingShingle | 610 Medicine & health Inal, Jameel Paizuldaeva, Ainura Terziu, Esmeralda Therapeutic use of calpeptin in COVID-19 infection. |
| title | Therapeutic use of calpeptin in COVID-19 infection. |
| title_full | Therapeutic use of calpeptin in COVID-19 infection. |
| title_fullStr | Therapeutic use of calpeptin in COVID-19 infection. |
| title_full_unstemmed | Therapeutic use of calpeptin in COVID-19 infection. |
| title_short | Therapeutic use of calpeptin in COVID-19 infection. |
| title_sort | therapeutic use of calpeptin in covid 19 infection |
| topic | 610 Medicine & health |
| url | https://repository.londonmet.ac.uk/7994/2/cs-2022-0638.pdf |
| work_keys_str_mv | AT inaljameel therapeuticuseofcalpeptinincovid19infection AT paizuldaevaainura therapeuticuseofcalpeptinincovid19infection AT terziuesmeralda therapeuticuseofcalpeptinincovid19infection |